Chime Biologics And Daewoong Pharmaceutical Partner To Advance Global Dupilumab Biosimilar Development
Chime Biologics, a biologics contract development and manufacturing organization (CDMO) based in China, has formed a strategic partnership with Daewoong Pharmaceutical, a leading South Korean pharmaceutical company, to develop and manufacture a biosimilar of Dupixent (dupilumab). The collaboration leverages Chime Biologics’ AI-enabled development platform and bioprocess supply chain ecosystem to support Daewoong’s global biosimilar ambitions, targeting the growing immunology market.
The partnership marks Daewoong Pharmaceutical’s entry into the biosimilars sector. Dupixent, co-developed by Sanofi and Regeneron Pharmaceuticals, generated approximately $17.8 billion in global sales in 2025, making it one of the world’s best-selling biologic medicines. Chime Biologics will utilize its end-to-end biosimilar development and commercialization experience to accelerate the project, with the goal of improving patient access to high-quality biologic medicines worldwide.
Benny Chong, Chairman of VMS Group, which holds a controlling stake in Chime Biologics, emphasized the strategic value of the collaboration, stating that Chime Biologics has built a differentiated platform serving both innovative biologics and biosimilars. Jimmy Wei, CEO of Chime Biologics, highlighted the competitive nature of the biosimilars market, noting the need for scientific excellence, manufacturing robustness, and global regulatory expertise.
Why It Matters
The partnership addresses the rising demand for biologic therapies, particularly in immunology, while also reflecting broader industry trends toward cost-effective alternatives. By entering the biosimilars market, Daewoong Pharmaceutical aims to diversify its portfolio and expand its global presence. The collaboration also underscores the role of AI and advanced manufacturing in streamlining biosimilar development, which could reduce time-to-market and costs for patients.
What May Happen Next
The partnership could position Daewoong Pharmaceutical as a key player in the biosimilars market, potentially leading to further collaborations or product launches. However, regulatory hurdles and competition from other biosimilar developers may influence the project’s timeline and success. Analysts suggest that the outcome will depend on the ability of both companies to navigate complex global markets and secure necessary approvals.
Did You Know? Dupixent, the reference drug for this biosimilar, generated $17.8 billion in global sales in 2025, highlighting the significant market opportunity for biosimilars in the immunology sector.
Expert Insight: The collaboration between Chime Biologics and Daewoong Pharmaceutical reflects a strategic move to capitalize on the expanding biosimilars market, which is driven by the need for affordable biologic treatments. By combining Chime’s technological capabilities with Daewoong’s global reach, the partnership could set a precedent for future cross-border collaborations in the biopharmaceutical industry.
Frequently Asked Questions
What is a biosimilar? A biosimilar is a biologic medical product that is highly similar to an already approved reference product, with no clinically meaningful differences in terms of safety, purity, and potency.
Why is this partnership significant? This partnership marks Daewoong Pharmaceutical’s entry into the biosimilars market, a sector expected to grow due to the expiration of patents on key biologic drugs like Dupixent.
How does AI play a role in this collaboration? Chime Biologics’ AI-enabled development platform is designed to enhance efficiency and accuracy in biosimilar development, potentially reducing time and costs associated with traditional methods.
As the project progresses, stakeholders will be watching how this collaboration impacts the competitive landscape of the global biosimilars market. What role do you think partnerships like this will play in shaping the future of biologic medicine?